Bermingham has enjoyed a front-row seat for the conception and launch of several dynamic biotech companies. Perhaps the best known is Intellia Therapeutics, one of the first wave of public CRISPR gene editing companies. Intellia celebrated a major milestone in June when it published results on the first half-dozen patients receiving an in vivo gene editing therapy for ATTR amyloidosis, a rare liver disease . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Running Up That Hill: Nessan Bermingham on Close to the Edge appeared first on GEN – Genetic Engineering and Biotechnology News.
